14. October 2009 01:01
Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers. The Phoenix Awards are presented for outstanding achievement in the medical device and diagnostic industry to individuals and companies selected by industry CEOs.
"Everyone at Novasys is deeply honored by this award, particularly since we were chosen by leaders in our industry," said Debra Reisenthel, Novasys President and Chief Executive Officer. "They know our non-surgical Renessa treatment offers women afflicted with stress urinary incontinence an opportunity to resume activities that make their lives fulfilling."
Attorney J. Casey McGlynn who is a partner with Wilson Sonsini Goodrich & Rosati and co-founder of the Phoenix Conference, commented, "Novasys' Renessa System joins an elite group of past award winners. That prestigious list includes large and small companies with groundbreaking technologies that changed the standard of medical care, including Conceptus' Essure device, JNJ/Cordis' drug eluting stent, and Boston Scientific's (Guidant's) implantable defibrillators."
Beckie Robertson, Managing Director with Versant Ventures and another founder of the Phoenix Conference, remarked, "The non-surgical Renessa treatment represents a true breakthrough in therapeutic options for stress urinary incontinence. Before this safe, effective, in-office treatment was available, women who failed conservative therapies such as Kegel exercises, and couldn't accept surgical risks or a long recovery, had very few options."
SOURCE Novasys Medical, Inc.
Subscribe